Note 3 - Licenses Supplier Agreements (Details Textual) - USD ($) $ in Millions |
1 Months Ended | 4 Months Ended | ||
|---|---|---|---|---|
Oct. 29, 2018 |
Feb. 17, 2015 |
Dec. 31, 2019 |
Jun. 17, 2015 |
|
| Revogenex License [Member] | ||||
| Contractual Obligation, Maximum Future Payments | $ 3 | |||
| Polpharma [Member] | ||||
| Payments to Acquire in Process Research and Development | $ 2 | |||
| Fortress Biotech Inc [Member] | Iv Tramadol [Member] | ||||
| Payments to Acquire in Process Research and Development | $ 2 | |||
| Fortress Biotech Inc [Member] | Iv Tramadol [Member] | Additional Payment [Member] | ||||
| Payments to Acquire in Process Research and Development | $ 1 | $ 1 |
| X | ||||||||||
- Definition Maximum future payments for contractual obligation. No definition available.
|
| X | ||||||||||
- Definition The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|